Peer-Reviewed Journal Details
Mandatory Fields
O'Gorman, DM,McKenna, SL,McGahon, AJ,Knox, KA,Cotter, TG;
2000
February
Official Journal of The Leukemia Society of America
Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals
Validated
()
Optional Fields
AML apoptosis Ras PI3-kinase Bcl-2 family ACUTE MYELOID-LEUKEMIA COLONY-STIMULATING FACTOR HEMATOPOIETIC-CELLS PROTEIN-KINASE PHOSPHATIDYLINOSITOL 3-KINASE MULTIDRUG-RESISTANCE RAS ONCOGENES BCL-2 EXPRESSION DEATH
14
602
611
Drug resistance remains a serious limiting factor in the treatment of acute myeloid leukaemia (AML) either at initial presentation or following primary or subsequent relapses. Using specific kinase inhibitors, this study has investigated the contribution of the Ras/PI3-kinase regulated survival pathways to drug resistance and suppression of apoptosis in a cell line derived from AML (HL60). Inhibition of the Raf/MAP-kinase (ERK) pathway with a specific MAP-kinase inhibitor, apigenin did not sensitise HL60 cells to drug-induced apoptosis, indicating a lack of involvement in chemoresistance. In contrast, the PI3-kinase inhibitors, LY294002 and wortmannin, did induce a significant increase in apoptosis in combination with cytotoxic drugs. The contribution of downstream mediators of PI3-kinase, p70S6-kinase and PKB/Akt were then investigated. While inhibition of p70S6-kinase with rapamycin did not increase drug-induced apoptosis, PI3-kinase inhibition resulted in notable dephosphorylation of PKB, suggesting that the PI3-kinase/PKB survival pathway may play a major role in chemoresistance in AML. This pathway has been reported to mediate heterodimer interactions with the proapoptotic regulator, Bad. In contrast to previous studies, we found no evidence of Bad binding to anti-apoptotic Bcl-2, Bcl-X-L or Mcl-1, or of alterations in Bar heterodimers. This suggests that alternative targets of PI3-kinase/PKB, distinct from the Bcl-2 family may be responsible for contributing to survival factor-mediated drug resistance in AML.
Grant Details